Wyeth docked US$490m for profiting from bogus claims on kidney drug Rapamune

Wyeth Pharmaceuticals has pleaded guilty to misbranding a drug that prevents the rejection of organ transplants and agreed to pay US$490.9 million, ...



via The Standard - Breaking News http://www.thestandard.com.hk/breaking_news_detail.asp?id=39323